USANA Health Sciences, Inc. (NYSE:USNA) Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 32.9% during the 2nd quarter, Holdings Channel.com reports. The fund owned 109,252 shares of the company’s stock after buying an additional 27,053 shares during the period. Assenagon Asset Management S.A.’s holdings in USANA Health Sciences were worth $4,943,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Dimensional Fund Advisors LP boosted its position in USANA Health Sciences by 3.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 677,664 shares of the company’s stock worth $36,323,000 after purchasing an additional 21,524 shares in the last quarter. CWM LLC boosted its position in shares of USANA Health Sciences by 21.8% in the 1st quarter. CWM LLC now owns 1,543 shares of the company’s stock worth $75,000 after buying an additional 276 shares in the last quarter. Strs Ohio grew its stake in USANA Health Sciences by 9.2% in the 4th quarter. Strs Ohio now owns 11,900 shares of the company’s stock valued at $637,000 after acquiring an additional 1,000 shares during the last quarter. Allianz Asset Management GmbH increased its holdings in USANA Health Sciences by 43.0% during the 4th quarter. Allianz Asset Management GmbH now owns 26,970 shares of the company’s stock valued at $1,446,000 after acquiring an additional 8,108 shares in the last quarter. Finally, Quest Partners LLC acquired a new position in USANA Health Sciences during the fourth quarter worth about $66,000. Institutional investors and hedge funds own 54.25% of the company’s stock.

Analyst Ratings Changes

USNA has been the topic of several research reports. DA Davidson lowered their price target on shares of USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating on the stock in a research report on Thursday, July 25th. StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th.

Insiders Place Their Bets

In other news, insider Paul A. Jones sold 2,714 shares of USANA Health Sciences stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $48.66, for a total value of $132,063.24. Following the completion of the sale, the insider now owns 6,266 shares of the company’s stock, valued at $304,903.56. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Paul A. Jones sold 2,714 shares of the company’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $48.66, for a total transaction of $132,063.24. Following the completion of the transaction, the insider now owns 6,266 shares of the company’s stock, valued at $304,903.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Myron W. Wentz sold 13,496 shares of USANA Health Sciences stock in a transaction on Friday, June 14th. The shares were sold at an average price of $45.03, for a total transaction of $607,724.88. Following the completion of the transaction, the insider now owns 7,864,345 shares in the company, valued at approximately $354,131,455.35. The disclosure for this sale can be found here. Insiders have sold a total of 30,052 shares of company stock valued at $1,336,549 in the last quarter. 0.33% of the stock is currently owned by company insiders.

USANA Health Sciences Trading Up 0.9 %

NYSE:USNA opened at $39.51 on Monday. USANA Health Sciences, Inc. has a 12-month low of $37.35 and a 12-month high of $65.27. The firm has a market cap of $752.71 million, a price-to-earnings ratio of 12.31, a price-to-earnings-growth ratio of 1.28 and a beta of 0.90. The company’s 50-day moving average is $43.79 and its two-hundred day moving average is $46.07.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, July 23rd. The company reported $0.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.11). The firm had revenue of $212.87 million for the quarter, compared to analysts’ expectations of $218.64 million. USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. During the same period in the previous year, the company posted $0.89 EPS. On average, equities research analysts forecast that USANA Health Sciences, Inc. will post 2.5 earnings per share for the current fiscal year.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.